Rohit Loomba, EASL ILC 2021: Rationale for Pemafibrate in NAFLD
It was a pleasure to speak with Prof. Rohit Loomba (University of California, San Diego, CA, USA) about the rationale for the use of the novel SPPARM inhibitor, pemafibrate, in the treatment of NAFLD.
Part 2 of our discussion can be found here.
His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness by MRE and serum liver and lipid parameters in NAFLD; a randomized, double-blind, placebo-controlled phase 2 trial’ was given at EASL ILC 2021, 23-26 June.
Disclosures: Prof. Rohit Loomba serves as a consultant for Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse Bio, Inipharm, Intercept, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, 89bio, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer and Siemens. He is also a co-founder of Liponexus, Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Peter Ferenci, EASL ILC 2022: Wilson’s disease – diagnosis and treatment
Wilson’s disease is a rare, genetic disorder characterized by the accumulation of excess copper in vital organs such as the liver and brain. Damage caused by the excess copper build-up can lead to symptoms of liver and neurological diseases. In this touchENDOCRINOLOGY interview, we speak with Prof. Peter Ferenci (Medical University of Vienna, Vienna, Austria) […]
Camilla Dalby Hansen, EASL ILC 2022: Non-calorie restricted, low carbohydrate, high fat diet for NAFLD in T2DM
touchENDOCRINOLOGY spoke with Camilla Dably Hansen (Odense Hospital, Denmark) about the findings from the recent 6-month randomised controlled trial investigating the impact of a non-calorie restricted, low carbohydrate, high fat diet on nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in patients with type 2 diabetes (T2DM). The abstract entitled ‘A non-calorie restricted […]
Aleksander Krag, EASL 2022: International Liver Congress Update
We caught up with the European Association for the Study of the Liver (EASL) Vice-Secretary, Prof. Aleksander Krag, to discuss the upcoming International Liver Congress (ILC) and what to expect. At ILC 2022 they will be bringing back face-to-face meetings in a new model, reshaping the scientific programme, offering a fresh experience, merging the very best […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!